Modality
ASO
MOA
AHRant
Target
GIP-R
Pathway
RAS/MAPK
ALS
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
~May 2017
→ ~Aug 2018
Phase 2
Nov 2018
→ Jul 2030
Phase 2Current
NCT08229550
1,463 pts·ALS
2021-12→2030-07·Active
NCT03557585
1,369 pts·ALS
2018-11→2026-01·Not yet recruiting
2,832 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-093mo agoPh3 Readout· ALS
2030-07-194.3y awayPh3 Readout· ALS
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Not yet…
P2/3
Active
Catalysts
Ph3 Readout
2026-01-09 · 3mo ago
ALS
Ph3 Readout
2030-07-19 · 4.3y away
ALS
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08229550 | Phase 2/3 | ALS | Active | 1463 | UPDRS |
| NCT03557585 | Phase 2/3 | ALS | Not yet recr... | 1369 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| NTL-2576 | Intellia | NDA/BLA | SGLT2 | |
| Terazumab | Rapport Ther | Phase 2 | BTK |